| William van der Touw |
William van der Touw is currently working as the Senior Vice President-Research & Development at Actinium Pharmaceuticals, Inc. |
| Avinash Desai |
Avinash Desai is currently the Chief Medical Officer at Actinium Pharmaceuticals, Inc. He previously worked as the Vice President-Global Medical Affairs at Eli Lilly & Co. and as the Vice President & Head-US Medical Affairs at Glaxo Smith Kline Biologicals NA. |
| Mary Mei Chen |
Mary Mei Chen is currently working as the Vice President-Clinical Development at Actinium Pharmaceuticals, Inc. Her former job was as a Medical Director at Takeda Pharmaceuticals International, Inc. She holds a doctorate degree from Shanghai Jiao Tong University and another doctorate degree from the Graduate School of Medicine University of Tokyo. |
| Monideepa Roy |
Monideepa Roy is currently the VP-Corporate Development, Research & Development at Actinium Pharmaceuticals, Inc. She previously worked as the Director-Research & Development at Akamara Biomedicine Pvt Ltd. and as the Vice President-Corporate Development & Operations at Akamara Therapeutics, Inc. She holds a doctorate degree from Jawaharlal Nehru University, a graduate degree from the University of Calcutta, and an undergraduate degree from Presidency College. |
| Akash Nahar |
Akash Nahar currently works at Drexel University, as Associate Professor and Actinium Pharmaceuticals, Inc., as Vice President-Clinical Development from 2022. Dr. Nahar received his graduate degree from State University of New York at Albany. |
| Elaina N. Haeuber |
Elaina N. Haeuber is currently the Vice President & Head-Clinical Operations at Actinium Pharmaceuticals, Inc. Prior to this, she worked as Vice President-Operations at WCG Clinical, Inc. She completed her undergraduate degree at Boston University and her graduate degree at the University of Illinois. |
| Caroline Yarbrough |
Caroline Yarbrough is currently the Chief Commercial Officer at Actinium Pharmaceuticals, Inc. Her former job was as a Portfolio General Manager-US Oncology at Novartis Oncology, Inc. She holds a doctorate degree from Nyenrode Business Universiteit, an undergraduate degree from the University of Delaware, and an MBA from Goizueta Business School-Emory. |
| Jenny Hsieh |
Jenny Hsieh is currently the Chief Strategy Officer at Actinium Pharmaceuticals, Inc. She previously worked as the Director of Corporate Strategy at Quest Diagnostics, Inc. and as the Head of Corporate Strategy at Immunomedics, Inc. Hsieh received an undergraduate degree from the University of Pennsylvania and an MBA from The Leonard N Stern School of Business. |
| Steve O'Loughlin |
Steve O'Loughlin is currently the Chief Financial & Accounting Officer at Actinium Pharmaceuticals, Inc. Prior to this, he was the Vice President-Corporate Finance & Development at Protea Biosciences Group, Inc. from 2012 to 2015. He completed his undergraduate degree at Ramapo College of New Jersey. |
| Lynn M. Bodarky |
Lynn M. Bodarky is currently the Chief Business Officer at Actinium Pharmaceuticals, Inc. Previously, she was the Vice President of Business Development at Geron Corp. from 2019 to 2021 and the Vice President of Marketing at Progenics Pharmaceuticals, Inc. from 2004 to 2007. She also held the position of Senior VP & Global Head of Business Development at HiFiBiO Inc. Ms. Bodarky has an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from The Wharton School of the University of Pennsylvania. |
| Sandesh Seth |
Sandesh Seth is currently the Chairman & Chief Executive Officer at Actinium Pharmaceuticals, Inc. He is also a Managing Partner at Jamess Capital Group LLC. Previously, he served as the Chairman of Relmada Therapeutics, Inc. from 2015 to 2017. He has also held positions as a Director at Actinium Pharmaceuticals, Inc., Cactus Ventures, Inc., Camp Nine, Inc., and Relmada Therapeutics, Inc. Additionally, he was the Head-Healthcare Investment Banking at Laidlaw & Co. (UK) Ltd. Mr. Seth holds an MBA from New York University and an undergraduate degree from the University of Mumbai. |
| Richard M. Stone |
Richard M. Stone is currently the Chief of Staff & Program Director at Actinium Pharmaceuticals, Inc. and a Trustee at Dana-Farber Cancer Institute, Inc. He received his doctorate degree from Harvard Medical School in 1981. |
| Jeffrey W. Chell |
Jeffrey W. Chell is the founder of the Center For International Blood & Marrow Transplant Research, which was founded in 2004. He held the title of Executive Director at the firm starting in 2004. Dr. Chell's current job(s) include Chief Executive Officer at the National Marrow Donor Program, starting in 2000 and continuing to the present. He is also currently serving as Chairman at CLR Insurance Ltd. since 2015. Additionally, he is an Independent Director at Actinium Pharmaceuticals, Inc. since 2018. He is a Member of the American Society of Hematology and the American Society for Blood & Marrow Transplantation. Dr. Chell's former job(s) include serving as Co-Chairman at Bone Marrow Donors Worldwide from 2014 to 2016. He also served as President at Allina Medical Clinic from 1994 to 1999. Dr. Chell obtained a doctorate degree from the University of Minnesota. |
| C. David Nicholson |
C. David Nicholson is currently the Vice Chairman at Transcelerate Biopharma, Inc., the Chairman at Exscientia AI Ltd., the Non-Executive Chairman at Wild Bioscience Ltd., the Director at Science Exchange, Inc., the Lead Independent Director at Actinium Pharmaceuticals, Inc., the Independent Director at Adverum Biotechnologies, Inc., the Director at Tarus Therapeutics, Inc., and the Director at Volastra Therapeutics, Inc. He is also an Operational Partner at Gilde Healthcare. In his former positions, Dr. Nicholson served as the Non-Executive Chairman at Exscientia Plc, a Director at Actinium Pharmaceuticals, Inc., a Director at Cactus Ventures, Inc., a Senior Vice President at Forest Laboratories, Inc., the Vice President-Licensing & Knowledge Management at Merck & Co., Inc., the SVP-Global Project Management & Drug Safety at Schering-Plough Corp., the Chief Technology Officer & Executive VP at Bayer CropScience AG, and the Executive Vice President-Research & Development at Organon International, Inc. and Organon Biosciences, Inc. He was also the Executive VP, Chief Research & Development Officer at Allergan Ltd. (Ireland) and the CTO, Head-Research & Development at Bayer Crop Science Solutions LLC. Dr. Nicholson obtained his undergraduate degree from The University of Manchester in 1975 and his doctorate degree from The University of Wales in 1980. |
| Ajit S. Shetty |
Ajit S. Shetty is currently the Chairman at Mcb Forum, Chairman at Rejuvenate Biomed, Chairman at YS Biopharma Co. Ltd., Director at Soudal NV, Independent Director at Actinium Pharmaceuticals, Inc., Independent Non-Executive Director at YishengBio Co., Ltd., Trustee at Carnegie Mellon University, Member-Supervisory Board at Cilag GmbH International, and Member-Governors Board at GS1 AISBL. In the past, Dr. Shetty served as Chairman at Janssen Pharmaceuticals, Inc. from 2004 to 2012, Chairman at Mithra Pharmaceuticals SA in 2021 and 2022, Chairman at Vlaams Instituut voor Biotechnologie - Flanders Institute, Chairman at Janssen Pharmaceutica NV from 2008 to 2017, Independent Director at Agile Therapeutics, Inc. from 2016 to 2023, Director at Saama Technologies, Inc., Director at reMYND NV, Director at Optimal Strategix Group, Inc., and Head-Enterprise Supply Chain at Johnson & Johnson from 2007 to 2012. Dr. Shetty's education includes an MBA from Carnegie Mellon University in 1974, an undergraduate degree from Trinity College, Cambridge, and a doctorate from Trinity College, Cambridge in 1972. |
| Richard I. Steinhart |
Richard I. Steinhart is currently an Independent Director at Atossa Therapeutics, Inc., Actinium Pharmaceuticals, Inc., and Chief Financial & Accounting Officer, Senior VP at BioXcel Therapeutics, Inc. He was previously an Independent Director at TG Therapeutics, Inc., Managing Director at Forest Street Capital, LLC, Managing Director at SAE Ventures, CFO & Vice President at Emisphere Technologies, Inc., CFO, Secretary, Treasurer & Senior VP-Finance at STRATA Skin Sciences, Inc., CFO & General Partner at CW Group, Inc., CFO & Vice President at Remedy Pharmaceuticals, Inc., and CFO & SVP-Finance at MELA Sciences Inc. He received his undergraduate and MBA degrees from Pace University. |
